Data Snapshots

Get It Delivered

Get research news and insights based on consensus data provided by Visible Alpha, delivered to your inbox.

Nov 19, 2024

Analysts Boost Sale Projections for Wave’s RNA-Editing Therapy Following Positive Early

Wave Life Sciences (NASDAQ: WVE) has marked a significant breakthrough in RNA-editing therapies with its alpha-1 antitrypsin deficiency (AATD) candidate, WVE-006. In an early-phase clinical trial, the therapy delivered the first…

Nov 15, 2024

UCB’s Bimzelx to Achieve Blockbuster Sales by 2025 with New U.S. Approvals

Less than a year after its initial FDA approval in plaque psoriasis, UCB’s (EBR: UCB) Bimzelx has added three new treatment indications, reinforcing its potential as a cornerstone drug in inflammatory diseases. In September,…

Nov 13, 2024

Affirm Forges New Path in Payment Solutions with New BNPL Card in Partnership with Visa

Affirm Holdings (NASDAQ: AFRM), a leading provider in the Buy Now, Pay Later (BNPL) sector, has partnered with payment processor Visa (NYSE: V) to launch an innovative payment card in the U.S. that integrates both debit and BNPL…

Nov 13, 2024

China Resources Power Accelerates Renewables Push as Thermal Sales Slide

China Resources Power (CRP) (HKG: 0846), one of China’s major independent power producers, is accelerating its shift towards renewable energy amid muted growth in its traditional coal and gas segments. Driven by the government’s…

Nov 12, 2024

BD Expands Smart Monitoring Portfolio with Edwards Lifesciences’ Critical Care Acquisition

In a strategic expansion of its medical technology offerings, BD (Becton, Dickinson and Company) (NYSE: BDX) announced in September the completion of its acquisition of Edwards Lifesciences' (NYSE: EW) Critical Care product line,…

Nov 07, 2024

XD’s Revenue Set for a Rebound as New Game Launches Drive 2024 Growth

After a challenging 2023, Chinese gaming company XD (HKG: 2400) is on course for a robust recovery, with revenues projected to jump by +53% year-on-year in 2024, supported by a strong rebound in gaming. The gaming segment, which…

Nov 06, 2024

Estée Lauder’s Outlook Dims as China and Travel Retail Weigh on Sales

Estée Lauder Companies (NYSE: EL) is navigating a turbulent year, facing falling sales and profits due to weakened consumer sentiment in China and weakness in Asia Travel Retail. For its first fiscal quarter, the luxury brand…

Nov 05, 2024

Ryanair’s Q1-Q2 Slide Prompts Lowered 2025 Forecast Amid Soft Demand and Cost Pressures

Ryanair (NASDAQ: RYAAY) grappled with a tough start to fiscal 2025 as a steep -15% drop in ticket prices dented first-quarter revenues and profits. The budget carrier downgraded its 2025 outlook, citing subdued consumer spending,…

Nov 05, 2024

Centessa Pharmaceuticals’ Sleep Disorder Drug Shows Early Promise, Accelerating Projections

Centessa Pharmaceuticals (NASDAQ: CNTA) recently announced positive interim data from a Phase 1 trial of its investigational drug, ORX750, aimed at addressing narcolepsy and other sleep-wake disorders. The trial, conducted in…

Oct 30, 2024

Zhihu Aims for Profitability Amid Revenue Headwinds

China’s largest Q&A platform, Zhihu (NYSE: ZH, SEHK: 2390), is bracing for a challenging 2024 as its main revenue streams—advertising, content commerce solutions (CCS), and paid memberships—face slowing growth. Advertising,…

Oct 29, 2024

Chinese Banks Brace for Slower Loan Growth Amid Economic Headwinds

China’s economic slowdown and property market downturn are set to dampen loan growth for the nation’s major banks in 2024, though demand from businesses is expected to keep overall lending growth resilient. Visible Alpha consensus…

Oct 29, 2024

Acelyrin Shifts Focus to Thyroid Eye Disease, Analysts Project Peak Sales of $1.2B by 2038

In August, Acelyrin (NASDAQ: SLRN) announced a strategic pivot from its lead asset, izokibep, used in treating hidradenitis suppurativa (HS) and psoriatic arthritis (PsA), to concentrate on lonigutamab. This anti-IGF-1R monoclonal…

Oct 24, 2024

Silicon Labs Poised for Rebound Despite Ongoing Market Headwinds

Silicon Laboratories (NYSE: SLAB) is navigating another tough year, as cyclical downturns in the semiconductor industry and stiff competition weigh on performance. Revenue is projected to drop -23% year-on-year in 2024, following…

Oct 22, 2024

Lumentum Eyes Turnaround After Tough FY24, with Strong Cloud & AI-Driven Growth Ahead

Lumentum Holdings (NASDAQ: LITE), a leader in optical and photonic technologies, faced a challenging FY 2024, with revenue falling -23% year-over-year. However, the company is poised for a recovery, with Visible Alpha consensus…

Oct 18, 2024

Travere Therapeutics Secures Full FDA Approval for Filspari, Expands Market Potential in IgA Nephropathy

Travere Therapeutics (NASDAQ: TVTX) secured a significant regulatory win on September 5, 2024, with the U.S. Food and Drug Administration (FDA) granting full approval for Filspari (sparsentan) as a treatment to slow kidney function…

Get it Delivered

Get articles like these including investment research news and insights uncovered using the Visible Alpha platform delivered to your inbox.

Subscribe Now